Literature DB >> 1147583

Double-blind comparison of phlebitis produced by cefazolin versus cephalothin.

N K Shemonsky, J C Carrizosa, D Kaye, M E Levison.   

Abstract

In a double-blind study with each patient as his own control, 1 g of cefazolin and 2 g of cephalothin were administered intravenously every 6 h to 20 patients in opposite arms for a period of 48 h each. The degree of phlebitis was significantly more severe with cephalothin than with cefazolin (P < 0.05); however, neither the incidence of phlebitis nor the time of onset of phlebitis was significantly different between the two drugs.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1147583      PMCID: PMC429165          DOI: 10.1128/AAC.7.4.481

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  Pharmacokinetics of cefazolin compared with four other cephalosporins.

Authors:  W M Kirby; C Regamey
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

2.  Cefazolin in the treatment of bacterial pneumonia.

Authors:  M Turck; R A Clark; H N Beaty; K K Holmes; W W Karney; L B Reller
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

3.  Evaluation of cefazolin in the treatment of bacterial endocarditis and bacteremia.

Authors:  J A Reinarz; C M Kier; J C Guckian
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

4.  Clinical and in vitro evaluation of cefazolin, a new cephalosporin antibiotic.

Authors:  K Ries; M E Levison; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1973-02       Impact factor: 5.191

  4 in total
  2 in total

1.  Comparative incidence of phlebitis due to buffered cephalothin, cephapirin, and cefamandole.

Authors:  S Berger; E C Ernst; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

Review 2.  Side effects of cephalosporins.

Authors:  S R Norrby
Journal:  Drugs       Date:  1987       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.